Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 11/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.53 |
| ▸ | METTL3 | Q86U44 | 3/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571878 | 0.91 | ADK (0.58) | ADKPRMT5WDR77METTL3DNMT1 | |
| SCHEMBL12300480 | 0.89 | ADK (0.62) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL6734286 | 0.89 | ADK (0.62) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL12154704 | 0.89 | ADK (0.62) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL12150798 | 0.89 | ADK (0.62) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL1738017 | 0.89 | ADK (0.62) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL12746910 | 0.89 | ADK (0.62) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL12831663 | 0.83 | ADK (0.66) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL14609525 | 0.83 | ADK (0.66) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL26554248 | 0.81 | ADORA3 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | ADK 3026/4885PRMT5 1878/4885WDR77 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.